Argenx continues to make strides with its VYVGART treatment for ocular myasthenia gravis, showing promising data from various trials and a recent approval from Health Canada for CIDP type. Expansion into ocular MG signifies VYVGART's growth and maturity. Despite a downturn due to continued oversold conditions, new data has reinvigorated hope for the first targeted treatment for ocular MG. Positive results from Phase 3 trials, including those for ARGX-124, have led to argenx's first profitable year with an impressive $1.3 billion in Q4 global product net sales. CEO changes were announced with Karen Massey replacing the outgoing officer. The company, however, faced setbacks with the discontinued trials of efgartigimod SC in thyroid eye disease and UplighTED. Notwithstanding, analysts remain confident with raised stock price targets from Bank of America and Oppenheimer, based on trial success and significant sales growth. Comprehensive data and research on myasthenia gravis and CIDP is set to be presented at the 2026 AAN annual meeting. The year ended with increased demand for VYVGART boosting Q4 results and a global partnership expansion with FUJIFILM Biotechnologies.
argenx News Analytics from Thu, 11 Sep 2025 07:00:00 GMT to Sat, 07 Mar 2026 11:59:03 GMT - Rating 8 - Innovation 6 - Information 9 - Rumor -5
